Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...

Tylah Tully looks at Vertex Minerals and the increasingly alluring gold grades coming out of its Reward gold mine in New ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex Minerals Ltd. ( ($AU:VTX) ) has issued an update. Vertex Minerals Ltd. has announced significant progress in its operations at the Reward ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all.

Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...

Vertex Resource Group Ltd. (“Vertex” or the “Company”) reports its financial and operational results for the third quarter ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...